Cargando…
Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'
We respond to concerns expressed by Pacifici and Shore (2019) about a recent paper (Lees-Shepard and Goldhamer, 2018a) in which we reported that the drug palovarotene can have severe side effects in a mouse model of fibrodysplasia ossificans progressiva.
Autores principales: | Goldhamer, David J, Lees-Shepard, John B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353591/ https://www.ncbi.nlm.nih.gov/pubmed/30698142 http://dx.doi.org/10.7554/eLife.43928 |
Ejemplares similares
-
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity
por: Lees-Shepard, John B, et al.
Publicado: (2018) -
Comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'
por: Pacifici, Maurizio, et al.
Publicado: (2019) -
Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1
por: Aykul, Senem, et al.
Publicado: (2022) -
A Network Pharmacology Study: Reveal the Mechanisms of Palovarotene Against Heterotopic Ossification
por: Huang, Junchao, et al.
Publicado: (2022) -
Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo‐Controlled, Double‐Blind Phase 2 Trial
por: Pignolo, Robert J., et al.
Publicado: (2022)